Gritstone Bio (GRTS) News and press releases

Gritstone Oncology's Return On Capital Employed Overview

15 Mar 23

Earnings

HC Wainwright & Co. Reiterates Buy on Gritstone Bio, Maintains $7 Price Target

14 Mar 23

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Sean Lee reiterates Gritstone Bio (NASDAQ:GRTS) with a Buy and maintains $7 price target.

12 Health Care Stocks Moving In Friday's After-Market Session

10 Mar 23

Movers

Gritstone Bio Cash, Cash Equivalents, Marketable Securities And Restricted Cash Were $185.2M As Of December 31, 2022, Compared To $223.5M As Of December 31, 2021

9 Mar 23

Earnings, News

Full Year 2022 Financial Results Cash, cash equivalents, marketable securities and restricted cash were $185.2 million as of December 31, 2022, compared to $223.5 million as of December 31,

Earnings Scheduled For March 9, 2023

9 Mar 23

Earnings

Companies Reporting Before The Bell • Aurora Mobile (NASDAQ:JG) is expected to report earnings for its fourth quarter.

Earnings Outlook For Gritstone Oncology

8 Mar 23

Earnings

HC Wainwright & Co. Maintains Buy on Gritstone Bio, Maintains $7 Price Target

15 Feb 23

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Sean Lee maintains Gritstone Bio (NASDAQ:GRTS) with a Buy and maintains $7 price target.

Gritstone bio And The National Cancer Institute Establish Clinical Trial Agreement To Evaluate A Neoantigen Cell Therapy-Vaccine Combination

14 Feb 23

Biotech, General

Under the terms of the agreement, NCI will identify patients with metastatic cancer that are eligible for adoptive cell transfer based on the presence of a G12V or G12D KRAS mutation (KRASmut). Gritstone will provide the

Gritstone bio to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 9, 2023

2 Mar 23

News, Press Releases

EMERYVILLE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced it will report its

Gritstone bio to Participate in 43rd Annual Cowen Healthcare Conference

27 Feb 23

Press Releases

EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that Andrew Allen,

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

27 Feb 23

Press Releases

EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the

Gritstone bio and the National Cancer Institute (NCI) Establish a Clinical Trial Agreement to Evaluate a Neoantigen Cell Therapy-Vaccine Combination

14 Feb 23

News, Health Care, Contracts, Press Releases, General

EMERYVILLE, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has entered

Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24 Jan 23

Press Releases

EMERYVILLE, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company that aims to develop the world's most potent vaccines, today announced that the company's

Gritstone bio to Participate in Upcoming Investor Conferences

18 Jan 23

News, Press Releases

EMERYVILLE, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (NASDAQ:GRTS), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that management will